ANTABIO SAS, a prominent player in the biopharmaceutical arena focused on crafting innovative therapies for severe drug-resistant bacterial afflictions, proudly announced Dr. Erick Lelouche’s appointment as the Chairman of its Board of Directors. Situated in Labège, France, Antabio’s decision to bring Dr. Lelouche on board marks a significant step in bolstering its commitment to combating antimicrobial resistance.
Dr. Lelouche, before his engagement with Antabio, was at the helm of the Boehringer Ingelheim Group in France since 2019, a role preceded by his leadership in the company’s Animal Health division and as Marketing Director for Human Health. His educational journey took him through the National Veterinary School of Nantes and the University School of Management of Montpellier, laying a solid foundation for his remarkable career in the pharmaceutical sector with giants like Pfizer and Boehringer Ingelheim. His tenure at Boehringer Ingelheim was notable for the launch of significant products in cardiology and pulmonology.
Marc Lemonnier, Antabio’s CEO and founder, expressed enthusiasm over Dr. Lelouche’s joining, emphasizing his extensive experience and valuable One Health perspective that will steer Antabio towards further successes in developing vital treatments against drug-resistant infections.
Dr. Lelouche shared his honor in joining Antabio’s pioneering team and expressed confidence in their combined expertise to make a substantial impact on patients worldwide grappling with drug-resistant infections.
Under Dr. Lelouche’s leadership, Antabio is set to enhance its innovative portfolio, including the lead program MEMANT3310, aimed at tackling hospital-acquired infections, and the PEi program, focused on developing a novel class of inhalation treatments for Pseudomonas aeruginosa infections affecting chronic pulmonary disease patients.
